PD-1/PD-L1抑制剂治疗的原发性非小细胞肺癌患者发生AKI的风险因素分析

IF 0.8 4区医学 Q4 UROLOGY & NEPHROLOGY

Iranian journal of kidney diseases Pub Date : 2024-04-25 DOI:10.5254/0n3xpz60

Jiong-Ming Ying, Feng Yan

引用次数: 0

摘要

研究原发性非小细胞肺癌（NSCLC）患者中程序性细胞死亡蛋白1（PD-1）、程序性细胞死亡配体1（PD-L1）抑制剂相关急性肾损伤（AKI）的风险因素，并构建预测模型。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor.

To investigate the risk factors of Programmed Cell Death Protein 1 (PD-1), Programmed Cell Death Ligand 1(PD-L1) inhibitor associated acute kidney injury (AKI) in patients with primary non-small cell lung cancer (NSCLC) and construct a predictive model.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Iranian journal of kidney diseases UROLOGY & NEPHROLOGY-

CiteScore

2.50

自引率

0.00%

发文量

审稿时长

6-12 weeks

期刊介绍： The Iranian Journal of Kidney Diseases (IJKD), a peer-reviewed journal in English, is the official publication of the Iranian Society of Nephrology. The aim of the IJKD is the worldwide reflection of the knowledge produced by the scientists and clinicians in nephrology. Published quarterly, the IJKD provides a new platform for advancement of the field. The journal’s objective is to serve as a focal point for debates and exchange of knowledge and experience among researchers in a global context. Original papers, case reports, and invited reviews on all aspects of the kidney diseases, hypertension, dialysis, and transplantation will be covered by the IJKD. Research on the basic science, clinical practice, and socio-economics of renal health are all welcomed by the editors of the journal.